Tusamitamab Ravtansine
Non-Small Cell Lung Cancer (CEACAM5+)
Phase 3Planned/Initiated
Key Facts
Indication
Non-Small Cell Lung Cancer (CEACAM5+)
Phase
Phase 3
Status
Planned/Initiated
Company
About LakeShore Biopharma
LakeShore Biopharma is a publicly traded company dedicated to addressing critical gaps in oncology and autoimmune disease treatment through a multi-faceted pipeline. The company has achieved key milestones by advancing multiple drug candidates into clinical development and securing strategic in-licensing agreements to bolster its portfolio. Its strategic direction involves progressing its lead assets through pivotal trials while exploring combination therapies and broader indications to maximize therapeutic impact and market potential.
View full company profile